Dr. Erhunmwunsee Discusses Disparities in Lung Cancer Treatment

Loretta Erhunmwunsee, MD
Published: Tuesday, Jan 16, 2018



Loretta Erhunmwunsee, MD, thoracic surgeon, assistant professor of surgery, City of Hope, discusses disparities in the treatment of lung cancer.

There are racial and socioeconomic disparities in every facet of lung cancer treatment, whether it is surgery, chemotherapy, or radiation therapy, says Erhunmwunsee. Factors with EGFR mutations and MET mutations can differ based on race. Disadvantaged groups are less likely to seek treatment, and are often less likely to survive.

Erhunmwunsee advises clinicians to be aware of these disparities and to provide support to groups with higher rates of mortality. She adds that if a patient had less education or a lower income, it could be beneficial to connect with social workers and treat the patient in a multidisciplinary fashion. These patients have more hurdles, and varying risk factors must be acknowledged and understood.
 


Loretta Erhunmwunsee, MD, thoracic surgeon, assistant professor of surgery, City of Hope, discusses disparities in the treatment of lung cancer.

There are racial and socioeconomic disparities in every facet of lung cancer treatment, whether it is surgery, chemotherapy, or radiation therapy, says Erhunmwunsee. Factors with EGFR mutations and MET mutations can differ based on race. Disadvantaged groups are less likely to seek treatment, and are often less likely to survive.

Erhunmwunsee advises clinicians to be aware of these disparities and to provide support to groups with higher rates of mortality. She adds that if a patient had less education or a lower income, it could be beneficial to connect with social workers and treat the patient in a multidisciplinary fashion. These patients have more hurdles, and varying risk factors must be acknowledged and understood.
 



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Oncology Best Practice™: Choosing Therapies for Patients with EGFR-mutant Lung Cancers: More Options... More Decisions... Better OutcomesApr 27, 20182.0
Community Practice Connections™: Translating Research to Inform Changing Paradigms: Assessment of Emerging Immuno-Oncology Strategies and Combinations Across Lung, Head and Neck, and Bladder CancersApr 28, 20182.0
Publication Bottom Border
Border Publication
x